dc.contributor.author |
Schellack, Natalie
|
|
dc.contributor.author |
Benjamin, Deon
|
|
dc.contributor.author |
Brink, Adrian J.
|
|
dc.contributor.author |
Duse, Adriano
|
|
dc.contributor.author |
Faure, Kim
|
|
dc.contributor.author |
Goff, Debra
|
|
dc.contributor.author |
Mendelson, Marc
|
|
dc.contributor.author |
Meyer, Johanna
|
|
dc.contributor.author |
Miot, Jacqui
|
|
dc.contributor.author |
Perovic, Olga
|
|
dc.contributor.author |
Pople, Troy
|
|
dc.contributor.author |
Suleman, Fatima
|
|
dc.contributor.author |
Van Vuuren, Moritz
|
|
dc.contributor.author |
Essack, Sabiha
|
|
dc.date.accessioned |
2017-11-22T08:24:30Z |
|
dc.date.available |
2017-11-22T08:24:30Z |
|
dc.date.issued |
2017-11 |
|
dc.description.abstract |
The Global Action Plan on antimicrobial resistance calls for the use of antimicrobial medicines in human
and animal health to be optimized, in tandem with a strengthening of the knowledge and evidence base
through surveillance and research. However, there is a paucity of consumption data for African countries
such as South Africa. Determining antimicrobial consumption data in low-resource settings remains a
challenge. This article describes alternative mechanisms of assessing antimicrobial consumption data,
such as the use of Intercontinental Marketing Services (IMS) data and contract data arising from tenders
(an open Request for Proposal, RFP), as opposed to the international norms of daily defined doses per 100
patient-days or per 1000 population. Despite their limitations, these serve as indicators of antimicrobial
exposure at the population level and represent an alternative method for ascertaining antimicrobial
consumption in human health. Furthermore, South Africa has the largest antiretroviral treatment
programme globally and carries a high burden of tuberculosis. This prompted the inclusion of
antiretroviral and anti-tuberculosis antibiotic consumption data. Knowledge of antimicrobial utilization
is imperative for meaningful future interventions. Baseline antimicrobial utilization data could guide
future research initiatives that could provide a better understanding of the different measures of
antibiotic use and the level of antibiotic resistance. |
en_ZA |
dc.description.department |
Veterinary Tropical Diseases |
en_ZA |
dc.description.librarian |
am2017 |
en_ZA |
dc.description.uri |
http://www.elsevier.com/locate/ijid |
en_ZA |
dc.identifier.citation |
Schellack, N. ... et al. 2017, 'A situational analysis of current antimicrobial governance, regulation, and utilization in South Africa', International Journal of Infectious Diseases, vol. 64, pp. 100-106. |
en_ZA |
dc.identifier.issn |
1201-9712 (print) |
|
dc.identifier.issn |
1878-3511 (online) |
|
dc.identifier.other |
10.1016/j.ijid.2017.09.002 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/63270 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Elsevier |
en_ZA |
dc.rights |
© 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
en_ZA |
dc.subject |
Antimicrobial governance |
en_ZA |
dc.subject |
Antibiotic consumption |
en_ZA |
dc.subject |
Developing country |
en_ZA |
dc.subject |
Antimicrobial exposure |
en_ZA |
dc.subject |
Antimicrobial resistance (AMR) |
en_ZA |
dc.subject |
Directly observed therapy, short course (DOTS) |
en_ZA |
dc.subject.other |
Veterinary science articles SDG-03 |
en_ZA |
dc.subject.other |
SDG-03: Good health and well-being |
|
dc.title |
A situational analysis of current antimicrobial governance, regulation, and utilization in South Africa |
en_ZA |
dc.type |
Article |
en_ZA |